According to the 2023 version of the National Comprehensive Cancer Network(NCCN) Ovarian Cancer Guidelines, patients with PSROC who have achieved CR or PR after last platinum-based chemotherapy, and have not received PARPi before, were advised to undergo maintenance therapy with PARP inhibitors. This evidence concerns the gene PARP1 and ovarian cancer.